Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Stéphane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Yigal Nochomovitz - Citigroup Ritu Baral - TD Cowen Sami Corwin - Wil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38210 _________ ...

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics' KB301 to Phase 2 aft ...

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 4, 2024, to discuss the financial results and provide a business update. Investors and the general public can access the live ...

Krystal Biotech, Inc. (KRYS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a c ...

Krystal Biotech (NASDAQ: KRYS ) is gearing up for a very important Q4 of 2024 because it is gearing up to report data from two different studies at that time. The first study of which is by using a clinical candidate He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make info ...

Krystal Biotech, Inc. (KRYS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate r ...

Shares of Krystal Biotech, Inc. (KRYS) , a commercial-stage biotechnology company, have surged 21.9% year to date compared with the industry's growth of 7.8%. The stock has also outperformed the Medical sector and S&P 500 Index during the same timeframe. The rally can be mostly attributed to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. Earlier this month, the company reported better-than-expected second-quarter results, wherein both earnings and sales beat their re ...

Second Quarter 2024 Financial Results and Business Update August 5, 2024 © Copyright 2024 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements and Disclosures Krystal | 2 This presentation, which includes the accompanying oral presentation, contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (together with its subsidiaries and affiliates, the "Compan ...

Krystal Biotech, Inc. (NASDAQ:KRYS) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - Senior Vice President, Patient Access, Analytics and Operations Christine Wilson - Senior Vice President and Head, U.S. Sales and Marketing Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank o ...